RxDoctor Payments Data

Peter Dyck, MD

Neurology · Rochester, MNNPI 1922086164

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $10,287 of the $11,927 with a category attached, or 86.2%. Akcea Therapeutics, Inc. accounts for 86.2% of it on its own, with 1 other manufacturer making up the rest.

$11,927in general payments, 2019–2025

Across 3 payments — averaging $3975.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akcea Therapeutics, Inc.$10K
  • Swedish Orphan Biovitrum AB$2K
$996,978in research payments, 2019–2025

Across 15 payments — averaging $66,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$959K
  • Ionis Pharmaceuticals, Inc.$38K

What the payments were for

  • Consulting fees$1,64014%
  • Travel & lodging$10,28786%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Akcea Therapeutics, Inc.2$10,287
Swedish Orphan Biovitrum AB1$1,640

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,927 in reported general payments places this provider in the 85th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$948
Medicare patients
17
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →